Navigation Links
NYSE Amex LLC Accepts Plan of Compliance of The Quantum Group, Inc.
Date:6/3/2009

WELLINGTON, Fla., June 3 /PRNewswire-FirstCall/ -- The Quantum Group, Inc. (NYSE Amex: QGP) (the "Company"), announced today that on May 28, 2009, the NYSE Amex LLC (the "Exchange") accepted the Company plan of compliance with respect to its previously disclosed listing deficiency as set forth in Section 1003(a)(iv) of the Exchange Company Guide. The Company was afforded the opportunity to submit a plan of compliance to the Exchange and on April 15, 2009 presented its plan to the Exchange, with subsequent submissions to the plan. On May 28, 2009, the Exchange notified the Company that it accepted the Company plan of compliance and granted the Company an extension until September 17, 2009, to regain compliance with the continued listing standards. The Company will be required to provide the Exchange staff with updates in conjunction with the initiatives of the plan of compliance as appropriate or upon the Exchange's request and the Exchange staff will review the Company periodically for compliance with the plan of compliance during the extension period. Failure to make progress consistent with the plan of compliance or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

About The Quantum Group, Inc.

The Quantum Group is an innovation-driven Healthcare Services Organization (HSO) that provides business process solutions, service chain management, strategic consulting and leading edge technology to the healthcare industry.

Quantum has developed and deployed PWeR(TM) (www.myPWeR.com), a cutting-edge, patent-pending healthcare technology system that has been designed to bridge the gaps of communication and exchange of patient information throughout the healthcare industry. To date eighteen provisional and one utility patent application have been filed in support of PWeR. The system can integrate all of the functions a physician/provider, hospital, clinic and related professionals utilize in one patient-centric, web-based platform and falls well within the economic incentives offered by the new $19 billion Stimulus Package for healthcare information technology. We believe we are positioned to be a catalyst for change as we take aim at the $700 billion inefficiency gap in the United States healthcare industry.

For more information, please visit http://www.QuantumMD.com.

Certain statements contained in this news release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial uncertainties and risks in part detailed in the Company's 10-K, 10-Q, 8-K and other filings with the SEC (and amendments thereto) that may cause actual results to materially differ from projections. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by these forward-looking statements. Such risk factors include, without limitation, the ability of the Company to properly execute its business model, to raise substantial and immediate additional capital to implement its business model, to attract and retain executive, management and operational personnel, to continue growing its patient base, to negotiate favorable current debt and future capital raises, to negotiate favorable agreements with a diversified provider base and to continue to supply the services needed by its HMO clients as well as physician clients. The Company does not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.

                     FOR MORE INFORMATION, PLEASE CONTACT:
                               RedChip Companies
                        Dave Gentry:  407.644.4256 x104
                               dave@redchip.com
                                      or
                             PR Financial Marketing
                           Jim Blackman: 713.256.0369
                              jim@prfmonline.com
                                      or
                            The Quantum Group, Inc.
                        Danielle Amodio:  561.798.9800
                             DAmodio@QuantumMD.com


'/>"/>
SOURCE The Quantum Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. United States Patent and Trademark Office Accepts CoolTouch's Re-examination Request for Cynosure '873 Patent
2. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
3. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
4. FDA Accepts Nuvos Resubmission For Pennsaid(R)
5. ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
6. Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute
7. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
8. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
9. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
10. Partnering With MyPyramid: NUTRIKIDS Accepts the Challenge to Help Families Step Up to Healthier Living
11. AMEX Accepts Lorus Plan to Meet AMEXs Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , ... February 27, 2017 , ... The threat of ... to work for a company involved in the underground testing of nuclear weapons. Years ... for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical ...
(Date:2/27/2017)... ... 2017 , ... Orange County dentist, Dr. A. Rassouli, comments on ... when the bacteria in plaque infect the gums and other tissues supporting the teeth. ... planing or SRP, and can include surgical therapies if the condition has led to ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media ... system brings songs, movies, TV shows and much more apps for user exploration. Its ... An immersive view of 1280 x 720 provides crisp images with remarkable clarity and ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count ... in March 2014. The company had 800 customers and 2,250 RCEs at the ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
(Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
(Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
Breaking Medicine Technology: